Targeted pill aims to shrink brain tumors with BRAF mutations

NCT ID NCT07688356

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This phase 2 trial tests belvarafenib, a daily pill that targets cancers with a BRAF mutation, in people with primary or metastatic brain tumors. Participants take the drug for about six months, and doctors monitor tumor response with scans. The goal is to see if the drug can control tumor growth and improve outcomes for this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belvarafenib (a targeted cancer drug taken as a pill)
What this could lead to: If successful, this could provide a new treatment option for people with brain tumors that have a specific genetic change (BRAF mutation).
What could go wrong: This is an early-phase study with only 30 participants, so results may not apply to everyone. The drug may cause side effects or fail to control tumor growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BRAIN TUMOR PRIMARY BRAIN TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.